Aduhelm: Case Study on Paying for Health by Paul Seegert

Insurance Thought Leadership - Nov 07, 2021

In July, I wrote an article that criticized the newly authorized Alzheimer’s drug Aduhelm. Six months later, the market response is heartening and, in my opinion, a case study in what it will take to fix the way that we pay for healthcare in America.  A review of the problem The FDA approved the fi...

Read Full Article